| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. [PubChem] |
| Indication |
For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females. |
| Pharmacology |
Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis, but its role as a treatment for endometriosis has been largely replaced by the gonadotropin-releasing hormone (GnRH) agonists. Danazol has antigonadotropic and anti-estrogenic activities. Danazol acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic, to principal metabolites, ethisterone and 17-hydroxymethylethisterone. |
| Half Life |
Approximately 24 hours. |
| References |
| • |
Dmowski WP: Danazol. A synthetic steroid with diverse biologic effects. J Reprod Med. 1990 Jan;35(1 Suppl):69-74; discussion 74-5.
[Pubmed]
|
| • |
Donaldson VH: Danazol. Am J Med. 1989 Sep;87(3N):49N-55N.
[Pubmed]
|
| • |
Jenkin G: Review: The mechanism of action of danazol, a novel steroid derivative. Aust N Z J Obstet Gynaecol. 1980 May;20(2):113-8.
[Pubmed]
|
|
| External Links |
|